Q1 2026 AVITA Medical Inc Earnings Call Transcript
Key Points
- AVITA Medical Inc (AVHHL) reported a revenue of approximately $19.3 million for Q1 2026, marking a 4% year-over-year increase and a 10% sequential growth from Q4 2025.
- The company has successfully stabilized its business operations and improved its operating cadence, leading to more consistent and predictable performance.
- AVITA Medical Inc (AVHHL) reaffirmed its full-year revenue guidance of $80 million to $85 million, indicating confidence in continued growth.
- The company achieved significant progress with its Cohelix product, including early-stage adoption and positive interim clinical data from the COHELYS-1 study.
- AVITA Medical Inc (AVHHL) secured a new long-term agreement with BARDA, providing a modest level of recurring readiness revenue and reinforcing the importance of its Resell product in emergency preparedness.
- Gross profit margin for Q1 2026 decreased to 81.7% from 84.7% in the prior-year period, primarily due to required inventory reserves and product mix changes.
- Net loss for the quarter was $10.6 million, although this was an improvement compared to the previous year's $13.9 million loss.
- Cash use was higher in Q1 2026, driven by seasonal compensation and other one-time payments, impacting cash flow negatively.
- The company is still in the process of educating healthcare systems and hospitals about reimbursement processes, which could delay full recovery in physician confidence.
- Despite progress, the company is still working through internal communication and education challenges to ensure consistent reimbursement for its Resell product.
Ladies and gentlemen, thank you for standing by, and welcome to Aveda Medical Inc. first quarter 2026 earnings conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. I would like now to turn the conference over to Ben Atkins. Please go ahead.
Thank you, operator. Welcome to Avita Medical's first-quarter 2026 earnings call.
Joining me on today's call are Kerry Vance, President and Chief Executive Officer and Daley O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website at www.avitamedical.com under the Investor Relations section.
Before we begin, I would like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1,995. These statements are neither promises nor guarantees and involve
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
